Narcolepsy drug shows promise for depression and ADHD in US, China, Japan

A treatment approved for narcolepsy in the US, China, and Japan is being investigated for broader psychiatric applications, including depression and ADHD. The claim of expanded efficacy is preliminary and based on researcher expectations rather than confirmed trial results. If validated, this could expand therapeutic options in major markets.